Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00054886 |
The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
Condition | Intervention | Phase |
---|---|---|
Kidney Neoplasms |
Drug: SU-011,248 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma |
Estimated Enrollment: | 63 |
Study Start Date: | January 2003 |
Study Completion Date: | August 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
Los Angeles, California, United States, 90095 | |
Pfizer Investigational Site | |
Mission Hills, California, United States, 91345 | |
Pfizer Investigational Site | |
Monterey Park, California, United States, 91754 | |
Pfizer Investigational Site | |
Northridge, California, United States, 91328 | |
Pfizer Investigational Site | |
San Francisco, California, United States, 94115 | |
Pfizer Investigational Site | |
San Francisco, California, United States, 94121 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02114 | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02115 | |
United States, Michigan | |
Pfizer Investigational Site | |
Ann Arbor, Michigan, United States, 48109 | |
United States, Nevada | |
Pfizer Investigational Site | |
Henderson, Nevada, United States, 89052 | |
Pfizer Investigational Site | |
Las Vegas, Nevada, United States, 89109 | |
Pfizer Investigational Site | |
Las Vegas, Nevada, United States, 89128 | |
United States, New York | |
Pfizer Investigational Site | |
New York, New York, United States, 10021 | |
United States, Pennsylvania | |
Pfizer Investigational Site | |
Philadelphia, Pennsylvania, United States, 19111 | |
United States, Wisconsin | |
Pfizer Investigational Site | |
Madison, Wisconsin, United States, 53792 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | RTKC-0511-014 |
Study First Received: | February 12, 2003 |
Last Updated: | May 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00054886 |
Health Authority: | United States: Food and Drug Administration |
Urologic Diseases Sunitinib Kidney Neoplasms Carcinoma, Renal Cell Urogenital Neoplasms Renal cancer |
Kidney Diseases Kidney cancer Urologic Neoplasms Urinary tract neoplasm Carcinoma |
Neoplasms Neoplasms by Site |